# Reviewer Remediation Compliance Review

Reviewer: Stacey S

Date: 2026-05-30

Scope: Validate the approved comorbidity expansion and medication specificity before applying Brainstorm SEND BACK remediation. This is not World Spec drafting.

## Source References

- New Writers Instruction Guide, lines 591-592: strong complexity examples include "Multiple active comorbidities (10+)" and "Polypharmacy (15+ medications)".
- Brainstorm template, `reference/templates/brainstorm.md`, line 7: World setup should include demographics, comorbidities, clinical environment, encounter type, and timeline shape.
- Brainstorm AutoQC historical output, `worlds/korvin-merrow/reviews/brainstorm-autoqc-01.md`, line 134: prior AutoQC commentary identified the case as borderline because the comorbidity list fell short of the 10+ threshold and the medication list did not approach 15 specific medications.
- Final Brainstorm AutoQC pass, `worlds/korvin-merrow/reviews/brainstorm-autoqc-02.md`, line 25: patient profile, comorbidities, setting, and clinical progression were realistic before reviewer SEND BACK.
- World Spec AutoQC v6.3 local index, `reference/world-spec-guidelines/08_autoqc_master_index.md`, check 2.12: the World Spec home medication list must include every drug with dose, route, frequency, and indication.
- World Spec AutoQC v6.3 local index, check 2.25: clinical complexity must cover interacting common conditions, competing recommendations, and diagnostic ambiguity.

## Threshold Finding

The source-of-truth guide does identify 10+ active comorbidities and 15+ medications as markers of a strong complex world. The Brainstorm template does not state a separate hard minimum count, but it does require comorbidities and enough clinical context to show coherence. The World Spec AutoQC emphasizes medication completeness, consistency, dose/route/frequency/indication, and multidimensional complexity rather than a separate numeric comorbidity-count check.

Practical implication: Stacey's SEND BACK is consistent with the guide and prior AutoQC complexity commentary. A compact Brainstorm-level medication list is acceptable if it is specific enough to show realistic polypharmacy and preserve the planned traps. The full dose/route/frequency/indication reconciliation can wait for World Spec after GO.

## Comorbidity Audit

| Candidate | Fit | Realism | Task complexity | Contradiction risk | Classification |
| --- | --- | --- | --- | --- | --- |
| Hyperlipidemia | Natural with CAD, diabetes, hypertension, and statin therapy. | Strengthens common cardiometabolic realism. | Supports CAD secondary prevention and discharge med review. | None. | Strongly Recommended |
| Anemia of CKD | Natural with CKD stage 3 and chronic disease burden. | Adds plausible fatigue/weakness background. | Strengthens "not all weakness is sepsis" without adding a new diagnosis. | Low if kept chronic/mild. | Strongly Recommended |
| Osteoporosis/osteopenia from chronic steroid exposure | Natural with chronic prednisone for PMR. | Strengthens steroid-risk realism. | Supports risk of unnecessary steroid continuation and bone-protection medications. | Low if not made central. | Strongly Recommended |
| Obstructive sleep apnea | Plausible in a 62-year-old cardiometabolic patient. | Adds realistic vulnerability to fatigue/cognition. | Supports discharge safety and functional status ambiguity. | Low if background only. | Reasonable |
| Diabetic peripheral neuropathy | Natural with long-standing diabetes. | Strengthens baseline fall/gait vulnerability. | Supports PT/family discharge-readiness concerns. | None. | Strongly Recommended |

Recommendation: Include all five approved additions. Do not add BPH or obesity for Brainstorm because the approved additions already reach the reviewer-requested burden without widening the case.

## Medication Audit

| Medication | Realism and consistency | Trap contribution |
| --- | --- | --- |
| Sacubitril/valsartan 24/26 mg BID | Plausible HFrEF guideline-directed therapy at a conservative dose compatible with hypotension/CKD concerns. | HF-AKI trap, medication reconciliation trap, discharge safety trap. |
| Carvedilol 12.5 mg BID | Plausible HFrEF/CAD therapy; may need holding or adjustment with hypotension/bradycardia. | HF-AKI trap, consultant conflict, discharge reconciliation. |
| Furosemide 40 mg daily | Plausible HFrEF volume medication. | Volume/AKI tension and restart/hold reasoning. |
| Spironolactone 25 mg daily | Plausible HFrEF MRA; CKD/AKI and potassium risk are clinically relevant. | HF-AKI trap, medication safety, discharge reconciliation. |
| Empagliflozin 10 mg daily | Plausible HFrEF/diabetes therapy; acute illness and AKI justify temporary holding. | HF-AKI trap, medication reconciliation, discharge safety. |
| Aspirin 81 mg daily | Plausible CAD secondary prevention. | Omission risk during discharge medication reconciliation. |
| Atorvastatin 40 mg nightly | Plausible CAD/hyperlipidemia therapy. | Long-term protective therapy continuity. |
| Metformin ER 500 mg BID | Plausible diabetes medication; CKD/AKI affects hold/restart reasoning. | Medication reconciliation and discharge safety. |
| Insulin glargine 18 units nightly | Plausible basal insulin for long-standing diabetes. | Inpatient vs discharge regimen confusion. |
| Prednisone with inconsistent documented taper/dose | Directly supports PMR and steroid timeline trap. | Steroid source-of-truth trap, Endocrinology friction, discharge safety. |
| Alendronate 70 mg weekly | Plausible bone protection with chronic steroid exposure/osteopenia. | Steroid-risk realism and med-list complexity. |
| Calcium/vitamin D daily | Plausible bone protection. | Background reconciliation detail. |
| Ferrous sulfate 325 mg every other day | Plausible anemia treatment. | Background med-list complexity; should not become central. |
| Gabapentin 300 mg nightly | Plausible diabetic neuropathy therapy; renal dosing and cognition/weakness matter in AKI. | Medication reconciliation, discharge safety, functional/cognitive ambiguity. |

## Reviewer Intent Comparison

Stacey requested four narrow fixes: unmistakably fictional identity, formal world type, stronger comorbidity burden, and named medication agents/doses. The current approved set addresses all four without redesigning the case.

A compact list should be sufficient for Brainstorm because the deliverable is still a concept pitch, not a World Spec medication table. However, the list should include drug names and doses in World Setup and should explicitly connect those medications to the HF-AKI and discharge-reconciliation complexity so the reviewer can see the remediation.

## Final Proposed Comorbidity Set

1. Type 2 diabetes mellitus
2. Hypertension
3. CKD stage 3
4. HFrEF
5. CAD history
6. Polymyalgia rheumatica with chronic prednisone/recent taper
7. Hyperlipidemia
8. Anemia of CKD
9. Osteoporosis/osteopenia from chronic steroid exposure
10. Obstructive sleep apnea
11. Diabetic peripheral neuropathy

## Final Proposed Medication Set

- Sacubitril/valsartan 24/26 mg BID
- Carvedilol 12.5 mg BID
- Furosemide 40 mg daily
- Spironolactone 25 mg daily
- Empagliflozin 10 mg daily
- Aspirin 81 mg daily
- Atorvastatin 40 mg nightly
- Metformin ER 500 mg BID
- Insulin glargine 18 units nightly
- Prednisone with inconsistent documented taper/dose
- Alendronate 70 mg weekly
- Calcium/vitamin D daily
- Ferrous sulfate 325 mg every other day
- Gabapentin 300 mg nightly

## Residual Risks

- The compact medication list has 14 medication entries if calcium/vitamin D is counted as one combined supplement. This is close to, but not strictly 15+. Reviewer intent is likely satisfied because the list is concrete and clinically load-bearing. If AutoQC or reviewer demands 15+ exactly, consider separating calcium and vitamin D or adding one physician-approved routine medication later.
- World Spec will require route/frequency/indication consistency across all medication lists. Brainstorm can remain compact, but these details must be expanded after Brainstorm GO.

## Recommendation

Apply the approved comorbidity and medication additions to the Brainstorm only. Do not add optional BPH or obesity. Do not change frictions, traps, tasks, timeline, or task workflow mappings. Regenerate the official-template DOCX and verify the four-section structure before any RL Studio reupload.
